Vaxil Bio Stock Today

VXL Stock  CAD 0.01  0.00  0.00%   

Performance

5 of 100

 
Weak
 
Strong
Modest

Odds Of Distress

Over 68

 
High
 
Low
Quite High
Vaxil Bio is selling for under 0.01 as of the 23rd of June 2024; that is No Change since the beginning of the trading day. The stock's lowest day price was 0.01. Vaxil Bio has more than 68 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Vaxil Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 24th of May 2024 and ending today, the 23rd of June 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
Category
Healthcare
Classification
Health Care
Vaxil Bio Ltd., an immunotherapy biotech company, engages in the research and development of immunotherapies for cancer and infectious diseases in Israel. The company was founded in 2006 and is headquartered in Toronto, Canada. VAXIL BIO is traded on TSX Venture Exchange in Canada.. The company has 136.98 M outstanding shares of which 3.73 K shares are at this time shorted by private and institutional investors with about 1.77 days to cover all short positions. More on Vaxil Bio

Moving against Vaxil Stock

  0.53BN BrookfieldPairCorr
  0.52AAPL Apple Inc CDRPairCorr
  0.51GOOG Alphabet CDRPairCorr
  0.47WMT Walmart Inc CDRPairCorr
  0.44NVDA NVIDIA CDR Earnings Call This WeekPairCorr

Vaxil Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Vaxil Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Vaxil Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO ChairmanDavid Goren
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Vaxil Bio's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Vaxil Bio's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Vaxil Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Vaxil Bio's financial leverage. It provides some insight into what part of Vaxil Bio's total assets is financed by creditors.
Liquidity
Vaxil Bio cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. Vaxil Bio has accumulated 85 K in total debt with debt to equity ratio (D/E) of 11.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vaxil Bio has a current ratio of 1.05, suggesting that it may not have the ability to pay its financial obligations in time and when they become due. Debt can assist Vaxil Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Vaxil Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vaxil Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vaxil to invest in growth at high rates of return. When we think about Vaxil Bio's use of debt, we should always consider it together with cash and equity.

End Period Cash Flow

668,798
Vaxil Bio (VXL) is traded on TSX Venture Exchange in Canada and employs 3 people. Vaxil Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.37 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Vaxil Bio's market, we take the total number of its shares issued and multiply it by Vaxil Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Vaxil Bio classifies itself under Biotechnology sector and is part of Health Care industry. The entity has 136.98 M outstanding shares of which 3.73 K shares are at this time shorted by private and institutional investors with about 1.77 days to cover all short positions. Vaxil Bio has accumulated about 307 K in cash with (561 K) of positive cash flow from operations.
Check Vaxil Bio Probability Of Bankruptcy
Ownership Allocation
Vaxil Bio maintains a total of 136.98 Million outstanding shares. Vaxil Bio has 8.16 % of its outstanding shares held by insiders and 0.01 % owned by institutional holders. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Vaxil Ownership Details

Vaxil Bio Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Vaxil Bio market risk premium is the additional return an investor will receive from holding Vaxil Bio long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vaxil Bio. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Vaxil Bio's alpha and beta are two of the key measurements used to evaluate Vaxil Bio's performance over the market, the standard measures of volatility play an important role as well.

Vaxil Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in Vaxil Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Earnings Calls Now

   

Earnings Calls

Check upcoming earnings announcements updated hourly across public exchanges
All  Next Launch Module

Additional Tools for Vaxil Stock Analysis

When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.